여성의 주요우울증에 대한 노에스액(육울탕)의 안전성, 유효성 평가 : 무작위배정, 양측눈가림, 위약대조, 평행설계 임상시험 프로토콜

키워드

참고문헌 (61)

1. The Korean Society of Oriental Neuropsychiatry Textbook Compilation Committee, "Oriental Neuropsychiatry", pp.249~259 (2016), Jipmoondang
2. Heo J, "Donguibogam", pp.1382~1386 (2006), Dongeuibogam Publishing House
3. Hwang UW, "Korean Psychiatry", pp.608~611 (1987), Hyeondae Medical Books
4. Mun JJ, "Oriental Pathology", pp.60~62 (1990), Gomunsa
5. The Korean Neuropsychiatric Association, "Textbook of neuropsychiatry", pp.273~280 (2017), iMiS Company
6. Cheon JS, "Neurobiology of Depression in Women", J. of Korean Geriatric Psychiatry, 3(2), pp.129~139 (1999)
7. Gongshin, "Gogeumuigam", pp.98~100 (1990), Scientific & Technical Publishing House
8. Bae GC, "Standard Clinical Medical Herbalprescriptions", Traditional Medicine Institute, 300~302 (1995)
9. Yang OS, "Gogeummyeongbang", pp.168~169 (1983), Scientific & Technical Publishing House
10. Lee SI, "Medical Herbalprescriptions", pp.228~229 (1998), Yeonglimsa
11. Cho YD, "Effect of Yukultang on the gastric ulcer and plasma Catecholamines contents of rats in immobilization stress", Collection of dissertations of Kyung-hee College of Korean medicine, 15(1), pp.431~448 (1992)
12. 조충식, "육울탕이 백서의 갑상선기능항진증에 미치는 영향", 대한본초학회지, 21(4), pp.11~17 (2006), 대한본초학회
13. 최영현, "六鬱湯에 의한 인체자궁경부암세포의 증식억제에 관한 연구", 동의생리병리학회지, 21(6), pp.1513~1519 (2007), 한의병리학회
14. 정선형, "六鬱湯의 산화적 스트레스에 대한 뇌세포 보호효과", 대한한방부인과학회지, 22(1), pp.15~30 (2009), 대한한방부인과학회
15. "Medicines Product Information"[URL]
16. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (1994), American Psychiatric Association
17. Klaus Linde, "St John's wort for depression - an overview and meta-analysis of randomised clinical trials", BMJ, 313(7052), pp.253~258 (1996)[DOI]
18. "ICH-GCP Guideline", International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical for Human Use (ICH) (2014)
19. Ministry of Food and Drug Safety, "KGCP Guideine", ~ (2000)
20. Ministry of Government Legislation, "Pharmaceutical Affairs Law" (2012)
21. Ministry of Government Legislation, "Bioethics and Safety Act" (2011)
22. Ministry of Food and Drug Safety, "HRPP Guideine", ~ (2014)
23. Korean Medical Association, "World Medical Association Declaration of Helsinki - Seoul revision : Ethical Principles for Medical Research Involving Human Subjects", J Korean Med Assoc, 53(9), pp.739~742 (2010)[DOI]
24. Lazarus,R.S, "Pattern of adjustment", pp.115~116 (1976), McGrew Hill
25. 장문규, "附子의 우울증 억제효과에 관한 연구", 동의신경정신과학회지, 20(3), pp.49~64 (2009), 대한한방신경정신과학회
26. Mohoney,M.J, "Abnormal psychology : Perspectives on human variance", pp.222~225 (1980), harper& Raw Publishers
27. Epidemiological survey of psychiatric illnesses in Korea, "Seoul National University College of Medicine", ~ (2011)
28. Korea Institute of Oriental Medicine, "Korean Medicine Clinical Practice Guideline for Depression", pp.34~37 (2016), Elsevier Korea L.L.C.
29. Bech P, "The Hamilton Depression Scale", Evaluation of objectivity using logistic models, 63, pp.290~299 (1981)
30. Rehm LP, "Item characteristics of the Hamilton Depression Rating Scale for Depression", J psychiat Res, 19, pp.31~41 (1985)[DOI]
31. Faries D, "The responsiveness of the Hamilton Deoression Rating Scale", J psychiat Res, 34, pp.3~10 (2000)[DOI]
32. 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구", 신경정신의학, 44(4), pp.456~465 (2005), 대한신경정신의학회
33. 윤서영, "효과적인 우울증 치료를 위한 임상평가도구", 대한정신약물학회지, 23(4), pp.136~146 (2012), 대한정신약물학회
34. Zimmerman M, "A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression", J Nerv Ment Dis, 192, pp.595~601 (2004)[DOI]
35. I. M. Hunt, "Suicide within 12 months of mental health service contact in different age and diagnostic groups: National clinical survey", British Journal of Psychiatry, 188(2), pp.135~142 (2006)[DOI]
36. Z. Rihmer, "Suicide risk in mood disorders", Current Opinion in Psychiatry, 20(1), pp.17~22 (2007)[DOI]
37. Park MS, "A Case Study of Meditation Counseling for Reducing Anxiety Disorder of Middle-aged Men Suffering from Panic Disorder", Journal of Meditation based Psychological Counseling, 15, pp.11~20 (2016)
38. 방규만, "주요 정신장애자들에서 수면의 질과 건강관련 삶의 질", 생물치료정신의학, 11(2), pp.138~149 (2005), 대한생물치료정신의학회
39. Fava GA, "Prodromal symptoms in primary major depressive disorder", J Affect Disorder, 19, pp.149~152 (1990)[DOI]
40. Lubin B, "Affect traits in differential diagnosis of anxiety, depressive, and schizophrenic disorders using the Multiple Affect Adjective Check List-Revised", Assessment, 5, pp.309~319 (1998)[DOI]
41. Rabin R, "EQ-5D: a measure of health status from the EuroQoL Group", Ann Med, 33, pp.337~343 (2001)[DOI]
42. Kim SH, "The EQ-5D-5L valuation study in Korea", Qual Life Res, 25, pp.1845~1852 (2016)[DOI]
43. Daut RL, "The prevalence and severity of pain in cancer", Cancer, 50, pp.1913~1918 (1982)[DOI]
44. 이현재, "세로토닌 재흡수 억제제, 세로토닌 노르에피네프린 재흡수 억제제, 노르아드레날린성 및 선택적 세로토닌성 항우울제가 통증에 미치는 효과 비교", 대한정신약물학회지, 23(4), pp.176~182 (2012), 대한정신약물학회
45. Park YN, "Psychiatric outpatients with physical symptoms", Keimyung Med J, 3, pp.169~174 (1984)
46. Song JY, "Frequency and clinical characteristics of pain of the patients in psychiatric outpatient clinics", J Korean Neuropsychiatr Assoc, 38, pp.1402~1411 (1999)
47. Bond MR, "Psychological aspects of pain in women with advanced cancer of the cervix", J Psychosom Res, 13, pp.13~19 (1969)[DOI]
48. 김유라, "기분장애 뇌신경기저에 대한 이해：뇌영상 연구를 중심으로", 생물정신의학, 18(1), pp.15~24 (2011), 대한생물정신의학회
49. Park K, "Jindanhaggwon-yeo", pp.491~492 (2000), Daesung Publishing Company
50. The Textbook Compliation Committee of Oriental Pathology, "Oriental Pathology", pp.172~ (2008), Hanimunhwasa
51. 이헌수, "우울증 변증도구의 신뢰도, 타당도 평가", 동의신경정신과학회지, 26(4), pp.407~416 (2015), 대한한방신경정신과학회
52. Mass,J.W, "3-Methoxy-4-hydroxyphenyl-glycol(MHPG) excretion in depressive states", Arch.Gen.Psychiatry, 19, pp.129~134 (1968)[DOI]
53. Goodwin, F.K, "5-HT and norepinephrine "subgroups" in depression. Metabolites findings and clinical pharmacological correlation", Sci. Proc.Am.Psychiatr.Assoc., 130, pp.108~131 (1977)
54. Christopher F. Sharpleya, "An update on the interaction between the serotonin transporter promoter variant (5-HTTLPR), stress and depression, plus an exploration of non-confirming findings", Behavioural Brain Research, 273, pp.89~105 (2014)[DOI]
55. PEZAWAS, L., "Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression", Molecular psychiatry, 13(7), pp.709~ (2008)[DOI]
56. Murer MG, "Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease", Prog Neurobiol, 63, pp.71~124 (2001)[DOI]
57. Shimizu E, "Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants", Biological Psychiatry, 54, pp.70~75 (2003)[DOI]
58. Lee YM, "Association Study Between Brain-Derived Neurotrophic Factor Genetic Polymorphism and Treatment Responses of Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder", Journal of Korean Geriatric Psychiatry, 12, pp.34~39 (2008)
59. DOWLATI, Yekta, "A meta-analysis of cytokines in major depression", Biological psychiatry, 67(5), pp.446~457 (2010)[DOI]
60. YOSHIMURA, Reiji, "Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression", Neuro-Psychopharmacology and Biological Psychiatry, 33(4), pp.722~726 (2009)[DOI]
61. FOSTER, Jane A., "Gut-brain axis: how the microbiome influences anxiety and depression", Trends in neurosciences, 36(5), pp.305~312 (2013)[DOI]

관련 논문AI추천